文献速递心外重症与机械循环支持

VA-ECMO支持心源性休克患者的临床结局:来自心源性休克工作组的多中心注册研究

Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.
PubMed 文献 · J Heart Lung Transplant · 2025-07-24

该回顾性多中心注册研究分析了2019至2023年间11,244例心源性休克患者中1,728例(15.3%)接受VA-ECMO支持的临床结局。结果显示总死亡率为51%,心肌梗死相关心源性休克死亡率更高(60% vs 42%,p<0.01),并发症发生率高。

要点

  • VA-ECMO用于心源性休克的总死亡率为51%,MI-CS死亡率60%高于HF-CS的42%。
  • HF-CS患者接受心脏替代治疗更常见(24% vs 7%),心脏移植率分别为71%和43%。
  • 主要并发症包括出血(53%)、肢体缺血(14%)和卒中(13%),MI-CS并发症高于HF-CS。

核心结论

  • 在大型当代真实世界心源性休克注册队列中,VA-ECMO支持的患者死亡率和并发症发生率均较高。

研究设计与样本

  • 回顾性分析心源性休克工作组多中心注册研究,2019至2023年共11,244例心源性休克患者,其中1,728例(15.3%)接受VA-ECMO。

主要发现

  • VA-ECMO患者中位年龄58岁,男性占69.9%;休克病因中心力衰竭占45%、心肌梗死占34%、其他占22%。
  • 总死亡率为51%,MI-CS死亡率60%高于HF-CS的42%(p<0.01)。
  • HF-CS患者心脏替代治疗更常见(24% vs 7%,p<0.01);HF-CS和MI-CS分别有71%和43%接受心脏移植。
  • 74%的VA-ECMO在非手术室场所置入,71%采用外周插管,34%使用远端灌注导管;71%的患者住院期间使用超过1种机械循环支持装置。
  • 并发症:急性肢体缺血总体14%(HF-CS 10% vs MI-CS 17%,p<0.01),出血总体53%(47% vs 56%,p<0.01),卒中总体13%(10% vs 16%,p<0.01)。

临床怎么用

  • VA-ECMO用于心源性休克时需警惕高死亡率和高并发症风险,尤其是MI-CS患者。

局限性

  • 本研究为回顾性注册分析,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) use for cardiogenic shock (CS) is increasing worldwide despite conflicting results from randomized trials, which focused on myocardial infarction-related CS (MI-CS). METHODS: We performed a retrospective analysis of the Cardiogenic Shock Working Group multicenter registry to assess outcomes in CS in those supported with VA-ECMO. Continuous variables were presented as mean±SD or median+IQR for normal/non-normal distributions. Group comparisons used the Student's t-test or Mann-Whitney U test for normal/non-normal data and chi-square test for proportions. RESULTS: Between 2019 and 2023, 1,728 out of 11,244 CS patients (15.3%) received VA-ECMO. Median age was 58 years, and 69.9% were male. Etiologies of shock were heart failure (HF-CS: 45%), myocardial infarction (MI-CS; 34%), and other-CS (22%). Mortality was 51% and higher for MI-CS (60% vs 42%, MI vs HF-CS, p < 0.01). Heart replacement therapy was more common among HF-CS patients (24% vs 7%, HF vs MI-CS, p < 0.01); 71% and 43% of HF- and MI-CS underwent cardiac transplantation. VA-ECMO was placed in a non-OR site in 74% of patients, predominantly with peripheral cannulation (71%). Distal perfusion catheters were used in 34% of VA-ECMO cases. In 71% of patients >1 MCS device was used during hospitalization. Complications included acute limb ischemia (14% overall, 10% vs 17%, HF vs MI-CS, p < 0.01), bleeding (53% overall, 47% vs 56%, HF vs MI-CS, p < 0.01), and stroke (13% overall, 10% vs 16%, HF vs MI-CS, p < 0.01). CONCLUSIONS: Using a large contemporary real-world CS registry, we report high mortality and complication rates with VA-ECMO. These findings may inform future shock trial designs.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Hernandez-Montfort J, John KJ, Goldstein D, et al. Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group. J Heart Lung Transplant. 2025. PMID: 40714159. doi:10.1016/j.healun.2025.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。